(주)모아바이오

YEASEN

[YEASEN] Recombinant Human Macrophage Inflammatory Protein-1 beta/CCL4 (Human MIP-1β/CCL4)

Cat-No. 90952ES

YEASEN은 생명과학 연구 및 진단을 위한 고품질의 연구용 시약과 기기를 제공하는 글로벌 바이오 기업입니다.

제품 설명

Recombinant Human Macrophage Inflammatory Protein-1 beta/CCL4 (Human MIP-1β/CCL4)

제품 번호

90952ES

제품 설명

Description

Both MIP-1α and MIP-1β are structurally and functionally related CC chemokines. They participate in host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells (e.g. macrophages, lymphocytes and NK cells). While both MIP-1α and MIP-1β exert similar effects on monocytes, their effect on lymphocytes differ; with MIP-1α selectively attracting CD8+ lymphocytes, and MIP-1β selectively attracting CD4+ lymphocytes. Additionally, MIP-1α and MIP-1β have also been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. Both human and murine MIP-1α and MIP-1β are active on human and murine hematopoietic cells.

Product Properties

Synonyms	G-26 T-lymphocyte-secreted protein, HC21, LAG-1, MIP-1-beta, PAT 744, Protein H400, SIS-gamma, Small-inducible cytokine A4, ACT-2
Accession	P48061
GeneID	6387
Source	E.coli-derived Human CCL4 protein,Gly21-Asn119.
Molecular Weight	Approximately11.6 kDa
AA Sequence	GKPVSLSYRC PCRFFESHVA RANVKHLKIL NTPNCALQIV ARLKNNNRQV CIDPKLKWIQ EYLEKALNKG RREEKVGKKE KIGKKKRQKK RKAAQKRKN
Tag	None
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Purity	> 96% by SDS-PAGE and HPLC analyses.
Biological Activity	Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using PHA and rHuIL-2 activated human peripheral blood T-lymphocytes is in a concentration range of 30-100 ng/mL.
Endotoxin	<0.1 EU/μg of protein as determined by LAL method.
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 150 mM NaCl.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.